Trial Profile
Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.
- 29 Jan 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov.
- 02 Jun 2015 Interim results (n=70) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.